Increased exposure (AUC) w/ strong CYP3A inhibitor eg, itraconazole, ketoconazole, ritonavir & clarithromycin especially in patients w/ mild to moderate renal impairment or mild hepatic impairment. Increased AUC & Cmax
of metoprolol, desipramine & digoxin. Caution in concomitant w/ drugs w/ narrow therapeutic index & significantly metabolized by CYP2D6 eg, thioridazine, type 1C antiarrhythmics (eg, flecainide, propafenone) & TCAs (eg, imipramine, desipramine). Potential P-gp inhibition of sensitive P-gp substrates eg, dabigatran.